Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant preventive dosing regimens in episodic migraine
2021-005239-22Phase 4Active
- Sponsor
- Pfizer
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of rimegepant in episodic migraine, migraine with aura and migraine without aura (3 arms), sponsored by Pfizer. Primary endpoint: Mean change in monthly migraine days. Started Apr 2022; status: active.
02
Drugs
rimegepant
03
Conditions
episodic migrainemigraine with auramigraine without aura
Beyond the preview
Go deeper on 2021-005239-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005239-22.